For a patient on Brilinta (ticagrelor) scheduled for hand ganglion cyst excision, is it safe to skip the antiplatelet dose on the morning of surgery?

No, skipping Brilinta only on the morning of surgery is NOT sufficient for hand ganglion cyst removal

For elective hand ganglion cyst excision in a patient taking Brilinta (ticagrelor), you must stop the medication 3-5 days before surgery, not just skip the morning dose. 1

Why Morning-Only Omission is Inadequate

Ticagrelor has a unique pharmacology that requires extended discontinuation:

• Half-life considerations: Ticagrelor's antiplatelet effects persist well beyond a single missed dose due to its active metabolites and reversible P2Y12 receptor binding
• Platelet function recovery: Studies show significant interindividual variability in platelet function recovery, with approximately 25% of patients still having inadequate platelet function even 72 hours after stopping ticagrelor 2
• The FDA label explicitly states: "When possible, interrupt therapy with BRILINTA for five days prior to surgery that has a major risk of bleeding" 3

Recommended Approach

Stop ticagrelor 3-5 days before the procedure 1:

• The 2022 American College of Chest Physicians guideline recommends stopping ticagrelor 3-5 days (not 7-10 days) before elective non-cardiac surgery
• For hand surgery specifically, a 5-day discontinuation is prudent given the confined surgical space where even minor hematomas can cause significant complications
• The French guidelines similarly recommend last intake on D-5 (5 days before procedure) 4

Critical Considerations

Assess the indication for Brilinta first:

• If the patient is on ticagrelor for recent acute coronary syndrome (within 1 year) or has coronary stents, coordinate with their cardiologist before stopping - the thrombotic risk may outweigh bleeding risk
• If for stable coronary artery disease beyond 1 year, the interruption is generally safer
• Never stop without cardiology input if the patient had a stent placed within the past 6-12 months - premature discontinuation significantly increases risk of stent thrombosis, MI, and death 3

Bleeding risk in hand surgery context:

• While recent evidence suggests continuing anticoagulation for some hand procedures may be safe 5, 6, 7, these studies primarily evaluated warfarin, aspirin, and clopidogrel - not ticagrelor
• Ticagrelor is more potent than clopidogrel and has shown higher bleeding rates in cardiac surgery when stopped <72 hours preoperatively 4
• Hand ganglion cyst excision, though minor, occurs in a confined space where hematoma formation can cause nerve compression, compartment syndrome, or wound complications

Practical Algorithm

1. Identify why the patient is on Brilinta (recent ACS/stent vs. stable CAD)
2. If recent ACS or stent (<12 months): Contact cardiology to discuss risk/benefit; consider delaying elective surgery
3. If stable indication: Stop ticagrelor 5 days before surgery (last dose on day -5)
4. Continue aspirin if the patient is also taking it - aspirin can typically be continued for hand surgery 5, 6
5. Resume ticagrelor as soon as hemostasis is achieved postoperatively, typically within 24-48 hours 1

Common Pitfall to Avoid

Do not treat ticagrelor like aspirin or other antiplatelet agents - it requires longer discontinuation than a single morning dose omission. The potent and prolonged antiplatelet effect means inadequate preoperative planning significantly increases bleeding complications, particularly in the 25% of patients who are slow metabolizers 2.